Physician

Howard S Zipin, M.D.

According to 2025 Medicare claims, Howard Zipin, M.D. (NPI: 1417939539) practices hematology/oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 18901-2554.

Zipin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 750 traditional Medicare patients, billed 214,671 HCPCS/CPT codes, and received $3,406,728 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,231 prescription claims across 237 beneficiaries totaling $5,406,123 in drug costs, led by Lenalidomide (Lenalidomide). 2015 DME data shows 52 claims. Open Payments data shows 108 records totaling $4,385. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,667,337 to $5,406,123. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	831	185,594	$2,567,377
2016	917	214,992	$3,345,780
2017	881	212,529	$3,766,295
2018	863	249,132	$4,255,258
2019	912	283,262	$4,601,825
2020	800	243,282	$3,897,204
2021	819	227,216	$4,093,376
2022	718	220,677	$3,997,763
2023	724	246,482	$3,907,473
2024	750	214,671	$3,406,728

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	206	994	$1,667,337
2016	192	1,054	$1,981,917
2017	192	1,068	$2,894,433
2018	216	1,038	$2,872,095
2019	221	1,101	$3,486,073
2020	214	1,174	$4,160,507
2021	194	1,002	$3,554,257
2022	218	1,061	$3,790,561
2023	201	971	$3,081,713
2024	237	1,231	$5,406,123

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	52	$4,570
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	237	499	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	246	346	$71
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	317	509	$13
36415	Insertion of needle into vein for collection of blood sample	173	572	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	144	570	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	92	2,387	$1,251,678
Brukinsa	Zanubrutinib	41	1,230	$591,735
Erleada	Apalutamide	34	1,020	$501,638
Calquence	Acalabrutinib Maleate	33	990	$491,700
Revlimid	Lenalidomide	15	420	$335,355

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	108	$4,385	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Howard S. Zipin, M.D.?

Tedicare shows public-source Medicare data for Howard S. Zipin, M.D. (NPI 1417939539), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Howard S. Zipin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Howard S. Zipin, M.D.?

Howard S. Zipin, M.D. is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Howard S. Zipin, M.D. have Open Payments data?

Howard S. Zipin, M.D. has 108 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.